This document is a published patent application from the USPTO for a new pharmaceutical formulation. The application, identified as US20260083690A1, describes dispersible pharmaceutical compositions containing N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and optionally a pharmaceutically acceptable carrier.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on drug manufacturers. However, it represents a step in the intellectual property protection process for novel drug formulations, which could impact future market exclusivity and product development strategies for pharmaceutical companies.